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Abstract Interleukin-la and/3 induced the production of large amounts of nitric oxide by normal, human articular chondrocytes in alginate culture; 
at the same time the biosynthesis of proteoglycan was strongly suppressed. In a dose-dependent manner, fl-monomethyl+arginine both inhibited 
nitric oxide formation and relieved the suppression of proteoglycan synthesis. However concentrations of Are-monomethyl-L-arginine which com- 
pletely prevented nitric oxide production only partially restored proteoglycan biosynthesis, even at low doses of interleukin-1 where suppression of 
proteoglycan synthesis was modest. The organic donor of nitric oxide, S-nitrosyl-acetyl-o,L- penicillamine also inhibited proteoglycan biosynthesis, 
but not as extensively as interleukin-1. These data suggest hat interleukin-1 suppresses synthesis of the cartilaginous matrix through more than one 
mechanism, at least one of which is dependent upon the production of nitric oxide. 
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1. Introduction 2. Materials and methods 
Interleukin-1 (IL-l) strongly suppresses the synthesis of pro- 
teoglycan (PG) molecules by normal, human, articular cartilage 
without eliciting a marked catabolic response ([ 1,2]; manuscript 
in preparation). 
2. I. Reagents 
As IL-l is synthesized within arthritic joints [3,4] it is likely 
to contribute to the loss of articular cartilage in arthritis by 
inhibiting synthesis of the cartilaginous matrix. The sensitivity 
of chondrocyte matrix synthesis to IL-l compromises the inher- 
ent repair capacity of cartilage. The ability of articular chon- 
drocytes to regenerate lost matrix may play a key role in pre- 
venting harmful pathological changes in the cartilage surface 
which lead to osteoarthritis. The mechanism through which 
IL-l inhibits PG synthesis by articular chondrocytes is un- 
known, 
IL-l also up-regulates expression of the inducible form of 
nitric oxide synthase (iNOS) within articular chondrocytes [5], 
leading to the synthesis of large amounts of nitric oxide (NO) 
[&9]. Indeed, synthesis of NO under these conditions is so great 
that it is unlikely to be irrelevant to the physiology of articular 
cartilage. However, almost nothing is known of the role that 
NO plays in chondrocyte metabolism. 
Pronase was purchased from Calbiochem, La Jolla, CA; collagenase 
(Clostridium histolyticum, type CLS-2) from Cooper Biomedicals, Cap- 
pel Worthington, Malvem, PA; Fetal bovine serum (FBS) was from 
Hyclone, Logan, UT; Ham’s Fl21DMEM medium from Gibco, Grand 
Island, NY, and low viscosity alginate (Keltone Lv) from Kelco, Chi- 
cago, IL. Sephadex G-25 (as prepacked PD-10 columns) was from 
Pharmacia, Piscataway, NJ. Radiolabelling was performed with 
[?S]sulphate, 25-40 Ci/mg, purchased from Amersham, Arlington 
Heights, IL. jV”-monomethyl+arginine (L-NMA) and fl-monom- 
ethyl-o-arginine (D-NMA) were kindly synthesized by Dr. Paul Dowd 
and Wei Zhang, Department of Chemistry, University of Pittsburgh, 
S-nitrosyl-acetyl-o,L-penicillamine (SNAP) purchased at Alexis Corp., 
Liiufelingen, Switzerland, human recombinant interleukin-lo and B 
(hrIL-lo.@) (Dr. Vosbeck, Ciba-Geigy, Basle) were a gift from Dr. P. 
Mtscher, Department of Rheumatology University Hospital, Univer- 
sity of Beme, Switzerland, human recombinant interleukin-1 receptor 
antagonist (hrIL-lra) was purchased at R&D Systems Europe Ltd., 
Abington, UK. Bisbenzimidazole fluorescent dye (Hoechst dye 
#33258) was purchased from Polysciences, Warrington, PA, papain, 
L-arginine and calf thymus DNA were from Sigma, St. Louis, MO. All 
other chemicals were reagent grade and purchased from several differ- 
ent companies. 
2.2. Cartilage sampling and isolation of chondrocytes 
In the present investigation, we have sought to determine the 
degree to which NO mediates the suppressive effect of IL-l 
upon PG biosynthesis by normal human, articular chondro- 
cytes. These studies were facilitated by the use of the alginate 
culture system, within which chondrocytes retain their differen- 
tiated phenotype [lo] and show almost identical behaviour to 
cartilage slice cultures when treated with IL-l ([I]; manuscript 
in preparation). 
Fresh human articular cartilage was obtained post-mortem from 
three organ donors between 39 and 55 years of age with no history of 
joint problems. Macroscopically normal cartilage from the weight- 
bearing parts of the medial and lateral femoral condyles were dissected 
under sterile conditions and immediately placed in cold Ham’s F-12/ 
DME (Dulbecco’s modified Eagle medium) medium supplemented 
with 5% fetal bovine serum (FBS). 
Chondrocytes were isolated from the harvested slices of human artic- 
ular cartilage by digestion of the extracellular matrix as published 
previously [1 I]. 
2.3. Cell culture in alginate beads 
*Corresponding author. Fax: (41) (1) 255-4415. 
Abbreviations: hrIL-1, human, recombinant interleukin-1; hrIL-lra, 
human, recombinant interleukin-1 receptor antagonist; NMA, No- 
monomethyl+arginine; NO, nitric oxide; NOS, nitric oxide synthase; 
PG, proteoglycan; SNAP, S-nitrosyl-acetyl-D,L-penicillamine. 
Chondrocytes were encapsulated and cultured in alginate beads as 
recently described by Guo et al. [12] and slightly modified by Hausel- 
mann et al. [ 111. Briefly, the isolated cells were suspended in sterile 0.15 
M NaCl containing low viscosity alginate gel (1.2%) at a density of 
4 x 1 O6 cells/ml of gel, then slowly expressed through a 22-gauge needle 
in a dropwise fashion into a 102 mM CaCl, solution. After instantane- 
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Fig. 1. Effect of hrIL-la and /3 on the biosynthesis of NO and sulphated proteoglycan by human articular chondrocytes in alginate cultures. 
(a,b) NO; content (nmol@g DNA) of culture supernatants of human articular chondrocytes, after I,2 and 3 days of treatment with different doses 
of hrIL-la and j3 (n = 4). (c,d) Inhibition of ‘5SO;2 incorporation into proteoglycan macromolecules by human chondrocytes, after treatment for 
3 days with different doses of hrIL-la and -/?, expressed as % of control (n = 3). x-Axes of Fig. Ic and Id have logarithmic scales. 
ous gelation, the beads were allowed to polymerise further for a period 
of 10 min in the CaCl, solution. After 1 wash in 10 volumes of 0.15 M 
NaCl and 3 washes in 10 volumes of Ham’s FlZ/DME medium, the 
beads finally were placed in 24 well plates and maintained by feeding 
daily 0.6 ml/well of Ham’s F-12IDME medium containing 50 j&/ml 
gentamicin, 25 &ml ascorbic acid and 10% FBS. The cultures were 
incubated at all stages in a humidified atmosphere of 5% CO* in air at 
37°C. 
2.4. Treatment of human chondrocytes in culture with hrIL-la@, hrIL- 
Ira, L-NMA, D-Nh4A. L-arginine and SNAP 
Seven days after encapsulation, the cells were treated daily for 3 days 
with the following agents either singly or in various combinations: 
l-500 pg/ml hrIL-la/B; 500 ng/ml hrIL-lra; O.Ol-1mM L-NMA; 1 mM 
D-NMA; l-100 mM L-arginine and 0.01 mM-1 mM SNAP. Other 
cultures were maintained as controls without additions. For each treat- 
ment regimen or control 4 culture wells with 5 beads/well were used. 
2.5. Proteoglycan biosynthesis 
After 3 days of treatment, Na;5S0, (20 ,UZi/ml final concentration) 
was added to the appropriate wells in triplicate and incubated for 4 h. 
After this period the labelling medium and alginate beads were ex- 
tracted at 4°C for 48 h by addition of an equal volume of 8 M guanidine 
hydrochloride (GuHCl), 20 mM EDTA and a mixture of proteinase 
inhibitors [14]. For quantitative valuation of ‘5S-labeled PGs, aliquots 
of the stored extracts were eluted on Sephadex G-25M in PD 10 col- 
umns under dissociative conditions [14]. The radioactivities of the 
newly synthesized PGs were measured by scintillation counting. 
2.6. Determination of DNA content in chondrocyte cultures 
DNA contents of the cultured chondrocytes were quantified using 
the bisbenzimidazole fluorescent dye, Hoechst 33258 [13]. Alginate 
cultures (one well per group), treated as mentioned above, were digested 
with papain (125 &ml) and evaluated in a spectrofluorometer as pub- 
lished earlier by Aydelotte and Kuettner [14]. 
2.7. Measurement of nitrite 
We have previously determined that NO generated by cultures of 
articular chondrocytes forms equimolar amounts of NO; and NO; as 
its stable in vitro end products [6]. NO production was thus measured 
as NO; formation using a spectrophotometric assay based upon the 
Griess reaction [15]. Nitrite concentration was measured in conditioned 
medium of quadruplicate cultures per group after 24, 48 and 72 h of 
treatment 
3. Results and discussion 
Addition of hrIL-la or hr IL-l/? to human articular chondro- 
cytes in alginate culture induced a dose-dependent production 
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Fig. 2. Effect of L-NMA on the biosynthesis of NO and sulphated proteoglycans by human articular chondrocytes in alginate culture in the presence 
or absence of hrIL-la or -jl (a) NO; released into the culture supernatants (nmol/pg DNA) by human chondrocytes after treatment for 2 days with 
different doses of L-NMA in the presence of 500 pg/ml hrIL-la or -p, expressed as % of control. (b) ‘5SO-,2 incorporation into proteoglycan 
macromolecules (cpm@g DNA) of human chondrocytes after treatment for 3 days with different doses of L-NMA in the presence of 500 pg/ml hrIL- I a 
or -/I, expressed as % of control. (c) Inhibition of “SOi incorporation into proteoglycan macromolecules of human chondrocytes after treatment for 
3 days with different doses of hrIL-la or /I in the presence or absence of 1 mM L-NMA. (d) NO; released into the culture supernatants (nmol/pg 
DNA) by human chondrocytes after treatment for 2 days with different doses of L-arginine in the presence of 500 pg/ml hrIL-IS and 0.1 mM L-NMA 
expressed as % of control (first bar shows NO; released in the presence of hrIL-l/7 alone). x-Axis in Fig. 2c has a logarithmic scale. 
of NO which continued during each of the three days in culture 
and showed a maximal response after 48 h of treatment with 
higher doses of IL-la/p (Fig. la,b). There was a corresponding 
dose-dependent inhibition of the incorporation of 35SO~z into 
PG (Fig. lc,d). hrIL-lra inhibited both NO production and the 
reduction in PG synthesis that occurred in response to hrIL-la 
and hrIL-l/3 (Table 1). Interestingly, hrIL-lra was significantly 
less effective (P 5 0.002) in relieving the suppressive ffect of 
IL-lb on PG synthesis than in relieving that of IL-la, an effect 
which was paralleled by the highly significant differential be- 
haviour of hrIL-lra on the inhibition of NO production in- 
duced by the two IL-I isoforms (P I 0.0002) (Table 1). The 
reason for this is unclear at present. However, it confirms other 
data of ours in experiments using the two isoforms of IL-l on 
human articular cartilage slice cultures (manuscript in prepara- 
tion). 
Two lines of evidence suggest that NO production is 
mechanistically linked to the suppression of PG biosynthesis 
occurring in these cultures. Firstly, L-NMA, a competitive in- 
hibitor of all isoforms of NOS which completely inhibited NO 
Table 1 
Effect of IL-lra on the biosynthesis of nitric oxide and sulphated pro- 
teoglycans by human articular chondrocytes treated with hrIL-la OR-/3 
Treatment NO; production PG-synthesis 
(nmol@g DNA) (?S-cpm/~g DNA) 
None 1.17 + 0.24 21599 + 1698 
IL-la 17.18 f 0.14 2770 f 58 
IL-I/? 17.32 f 0.6 2439 + 41 
IL-lra 1.91 f 0.18 22923 f 472 
IL-la + IL-lra 1.6 + 0.25 
IL-IS + IL-lra 3.73 f 0.4 1 * 21469 f 638 16405 f 785 1 ** 
IL-la and IL-l/l were added at a final concentration of 0.5 ng/ml; 
IL-lra was added at a final concentration of 500 q/ml. Values repre- 
sent NO; production during the 2448 h culture period. PG-synthesis 
denotes newly incorporated “SOL into proteoglycan macromolecules 
(cpm/pg DNA). Student’s t-test for independent sets of data (cultures 
treated with IL-la + IL-lra in comparison with IL-l/3 + IL-lra) was 
used for statistical analysis and P 5 0.05 was considered significant. 
*P 5 0.0002; **P 5 0.002; means + S.D. (n = 4 for nitrite production; 
n = 3 for PG synthesis). 
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Fig. 3. Effect of SNAP on the biosynthesis of NO and sulphated pro- 
teoglycans by human articular chondrocytes in alginate cultures. 
(a) NO; content of culture supematants 2days after addition of differ- 
ent doses of SNAP. (b) Inhibition of ‘SOi incorporation into pro- 
teoglycan macromolecules (cprn/pg DNA) after 3 days of treatment 
with different doses of SNAP, expressed as % of control. 
production (Fig. 2a), partially restored PG biosynthesis (Fig. 
2b) in a dose-dependent fashion. However, restoration of PG 
synthesis was never complete, even at low doses of IL-l which 
inhibited PC synthesis only modestly (Fig. 2~). D-NMA failed 
to inhibit NO production and had no effect on PG biosynthesis 
either in the presence or absence of IL-l (data not shown). 
Attempts were made to reverse the inhibitory effects of L-NMA 
by adding L-arginine. As shown in Fig. 2d, 1 mM and 10 mM 
arginine partially reversed the inhibitory effect of L-NMA on 
NO biosynthesis. But 100 mM arginine was inactive and appar- 
ently toxic. Similar toxicity has been noted previously in cul- 
tures of rabbit articular chondrocytes [6]. Such toxicity may 
help explain why arginine was unable to reverse the inhibition 
of PG synthesis in the present study (data not shown). This 
problem is exacerbated by the the high concentration of 
L-arginine in commercial culture medium (&5 mM in DMEM; 
1 mM in Ham’s F12). These concentrations are far in excess of 
the normal serum level of arginine (= 100 PM). 
The hypothesis that NO inhibits PG synthesis was supported 
by the ability of SNAP, a chemical donor of NO (Fig. 3a), to 
suppress PG biosynthesis. SNAP mimicked IL-l in reducing 
PG biosynthesis by chondrocytes in a dose-dependent manner 
(Fig. 3b). The maximum inhibition produced by SNAP failed 
to achieve that produced by IL-l, even though the total amount 
of NO generated was four-fold higher. However, the inhibition 
of PG synthesis achieved by SNAP was approximately equal 
to the inhibition achieved by that component of the IL-l effect 
which was sensitive to L-NMA (compare Figs. 2b and 3b). 
Collectively, these findings suggest that IL-l inhibits PG 
synthesis through more than one mechanism, not all of which 
require NO. 
Similar data to ours have recently been communicated in 
abstract form by Hickery et al. [16], who studied slices of nor- 
mal, human articular cartilage. Qualitatively similar findings 
have also been reported for lapine articular cartilage [17], sug- 
gesting that this might be a general mechanism of modulating 
cartilage matrix biosynthesis. 
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